Oral Drug Delivery System: A Review

Ms. Hina Umar Momin*, Prof. Santosh Waghmare, Dr. H. V. Kamble

Department of Pharmaceutical Chemistry¹, Department of Pharmaceutical Chemistry², Department of Pharmacology³

¹, ², ³ Lokne Shri Dadapatil Phara College of Pharmacy, Mandavgan Pharaa.

ABSTRACT: Oral administration of medicine in one of the preferred route and extensively used expression for new living and new medicines. The new generation of oral medicine delivery system technologies brings precious benefits to cases. Oral route is the most accessible and generally route of medicine delivery. It might be due to its ease of administration and utmost impotently patient compliance. Oral controlled release phrasings are designed to deliver a medicine at a pre determined rate by achieving a constant medicine position for a specified period of time with lower side goods. Controlled release medicine delivery have come a significant precedence worldwide, it may be possible to achieve rapid-fire immersion of medicine and increased memoir vacuity, reduced toxin and bettered patient compliance. The oral route is by far the most common route of medicine administration in the gastrointestinal tract and can be used for both systemic medicine delivery and for treating original gastrointestinal conditions. It's the most favored route by cases, due to its advantages, similar as ease of use, non-invasiveness, and convenience for tone-administration. Phrasings can also be designed to enhance medicine delivery to specific regions in the upper or lower GI tract. The upper GI tract consists of the mouth, pharynx, esophagus, stomach, and the first part of the small intestine (duodenum), whereas the lower GI tract includes the other corridor of the small intestine (jejunum and ileum) and the large intestine (cecum, colon, and rectum) (1,2). Medicines administered via the oral route, still, generally have slower immersion, which isn't preferred during an exigency (3, 4). They might also be unwelcome in taste, beget gastric vexation, and/ or suffer first-pass medicine elimination processes in both the intestine and liver (5,6). In addition, the physiological terrain in the GI tract can also affect the stability and solubility of medicines (7,8).

There are generally three main pretensions in expression design for the oral route of gastrointestinal medicine delivery (9,10) (i) original medicine delivery to treat gastrointestinal complaint, whereby the medicine generally needs to be taken up into gastrointestinal mucosa but won't be systemically absorbed or will be inadequately absorbed; (ii) systemic medicine delivery, where medicine immersion needs to be suitable to cut the mucosal wall into the systemic rotation; and (iii) increase dissolution rate of inadequately answerable medicines, which generally doesn't bear the expression to cross the mucosa or cells. Medicine immersion in the GI tract is governed by numerous factors similar as face area for immersion, blood inflow to the point
of immersion, the physical state of the medicine (similar as a result, suspense or solid lozenge form), its water solubility, and the attention of the medicine at the point of immersion (11, 12). For immersion to do, medicines must be suitable to access the epithelium, which is the immost subcaste that forms a nonstop filling of the entire GI tract. This epithelial cell hedge widely regulates transport from the lumen to the underpinning towel cube. Medicine motes can be transported passively via paracellular prolixity (between cells) and transcellular prolixity (through the cell) or laboriously via receptor-intermediated endocytosis and carrier-intermediated transport. Of these pathways, the transcellular route is the main medium of medicine immersion in the GI tract and is generally commensurable to the lipid solubility of the medicine (13,14). Thus, immersion is favored when the medicine patch is in thion-ionized form, which is much further lipophilic than the ionized form. Oral medicine delivery is a significant area of expression exploration due to the forenamed advantages for cases. Significant pharmaceutical advances have been made to ameliorate the indigenous targeting of medicines in the GI tract, still veritably many of them have restated to the clinical phase. This review will bandy the physiological, pathophysiological, and pharmaceutical considerations impacting medicine delivery for the oral route of administration, as well as the conventional and new medicine delivery approaches. The translational challenges and development aspects of new phrasings will also be addressed.

Biomedical exploration has advanced our understanding of conditions — their causes and remedies. Specifically, the reme-dies that include approaches to help, manage, or treat a particular complaint using a medicine (e.g., chemical and birth motes) or a medicine-suchlike (e.g., supplements) emulsion. The pace at which new conditions, newer pathways of formerly known conditions, and adding understanding of the medicine-resistant mechanisms are being uncovered is accelerating. This pace isn’t met by the discovery of new and effective drugs (15, 16). To meet this gap, adding attention is paid toward medicine displacing, where an being medicine discovered for a specific target is repurposed for other targets (). The primary advantage of medicine repurposing is that scientists formerly understand the pharmacology and safety biographies that can greatly reduce the threat of waste in medicine development in clinical phases. The medicine repurposing backed by artificial intelligence, systems pharmacology, and other computational approaches validate the medicine targets (19, 20). The effective delivery strategies would ameliorate threat- benefit biographies and switch routes of administration (21, 22). Each mode of delivery similar as oral, nasal, injection, sublingual, rectal, vaginal, optical, optical, or nasal has its separate advantages and disadvantages (23, 24). Nonetheless, oral medicine delivery ( capsules, maquillages, dormancies, and results) is the singular, superior system of administration due to its convenience and safety compared with other styles (25, 26). Enterocytes, tableware cells, and Peyer’s patches with M cells make the intestinal epithelium an optimal platform for medicine immersion. Especially regarding conditions that bear frequent administra-tion for a long duration, patient comfort proves oral medicine delivery’s eminence. The advantages of oral medicine administra-tion over other styles include ease of use, being effortless, lower cost of care, lower patient supervision, and advanced patient compliance.

Still, the oral route of medicine administration has some disadvantages when it comes to the medicine motes flaunting low solubility, lower permeability, and declination rates. Also, the uptake of certain biomolecules/medicines in oral route is largely affected by physiologic walls similar as pH change in gastrointestinal tract (GIT) acidic pH in the stomach followed by introductory pH in the intestine and enzymatic declination (27, 28). Nearly 60 of medicines de-grade in the harsh gastric surroundings of the stomach. Numerous have theorized making mariners out of the medicines, thereby in-furrowing its solubility and bioavailability (29, 30). Unfortunately, in practice, pairing the parent medicine with an applicable counter ion, for sufficient ionic commerce, has proven delicate. Only under ideal thermodynamic conditions will the swab medicine precipitate. Likewise, counter ions increase the weight of the medicine but are therapeutically inactive, therefore dragooning increased and frequent lozenge, which has necessary side goods on the body. Also, these fight ions increase the hygroscopic nature of the medicine by forming hydrates, and in consequence, reduce the medicine’s shelf life. Some counter ions also parade a sharp nature, like hydrochlorides, and hence reduce the solubility of the medicine in the stomach as explained by the counter ion effect (31, 32). These issues motivated experimenters to attempt innovative forms of con-ventional carriers like capsules, tablets, microcapsules, ornon-
conventional approaches similar as intestinal patches and nanoparticles. The successes with non-conventional delivery systems corroborate our belief that oral delivery deserves further attention for its possible advantages. The recent developments in the area of oral controlled release delivery systems similar as patch tablets, binary medicine tablets, intestinal patches, polymer nanosystems, or biosins-pired delivery systems similar as exosomes, have revolutionized the field. This review is an attempt to epitomize the oral medicine delivery ways available and under development, with current status for use and unborn prospects.

Modified oral release medicine delivery system has been developed to extend the medicine release for several hours (by combining medicine with release-retardant material to form matrix core or by applying release modifying film fleece over the core medicine material). The MR system offers reduction in dosing frequency, low prevalence of side goods and better remedial effect and improvement of bioavailability.

Table no 1: Approximate Fluid Flux, pH, and Residence Time within the gastrointestinal tract

<table>
<thead>
<tr>
<th>Section</th>
<th>Fluid</th>
<th>input/day (ml)</th>
<th>Output/day (ml)</th>
<th>pH</th>
<th>Residence time (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouth</td>
<td>Water</td>
<td>1200</td>
<td>1500</td>
<td>1.5</td>
<td>0.5-12</td>
</tr>
<tr>
<td>Stomach/Gastric</td>
<td>Fluid</td>
<td>2000</td>
<td></td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>Pancreas juice</td>
<td>500</td>
<td></td>
<td></td>
<td>6.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Duodenum</td>
<td>500</td>
<td></td>
<td></td>
<td>6.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Bile</td>
<td>500</td>
<td></td>
<td></td>
<td>6.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Jejunum</td>
<td>Intestinal secretion 1500</td>
<td>8500</td>
<td></td>
<td>7.2</td>
<td></td>
</tr>
<tr>
<td>Intestine</td>
<td>8500</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ileum</td>
<td>350</td>
<td></td>
<td></td>
<td>6.4</td>
<td>10.4</td>
</tr>
<tr>
<td>Colon</td>
<td>Fluid transfer 500</td>
<td>350</td>
<td></td>
<td>6.4</td>
<td>10.4</td>
</tr>
</tbody>
</table>

The rate of gastric emptying depends on state and size of lozenge form and the presence and composition of food, intestinal conveyance time etc., hence there must be interplay between GI physiology and expression design for the success of modified release medicine product (37, 38).

Factor impacting performance of modified medicines expression

Food
The influence of food on the bioavailability of medicine must be delved for safety and efficacy. If any food goods are plant also a justified cure with respect to the product input in relation to refections is given4.

Physiological and physicochemical factors affecting Modified release Technology
The mortal GI tract is a complex organ. The physiological factors that control immersion of medicine include Gastrointestinal transient time. Fluid and food input, gastric and intestinal stashing, absorptive medium, pH metabolism. The physicochemical factors include solubility, stability, ionisation and lipophilicity. By controlling both physiological and physicochemical factors we can successfully design modified release medicine delivery system. The topmost challenge in the design modified release phrasings is changing the nature of immediate release of the small intestine and extended release medication throughout the small intestine and eventually colon (33, 34).

Conveyance time in GI tract is also one of the major factors that affect the effectiveness of MR lozenge form as it directly influences the point of medicine release. Different the point of medicine release bear change in pH and water content on posterior medicine immersion (35,36).

Table: Approximate Fluid Flux, pH, and Residence Time within the gastrointestinal tract

<table>
<thead>
<tr>
<th>Fluid Flux</th>
<th>pH</th>
<th>Residence Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>1.5</td>
<td>0.5-12</td>
</tr>
<tr>
<td>Gastric</td>
<td>2.5</td>
<td>3.4</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>6.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Duodenal</td>
<td>6.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Biliary</td>
<td>6.3</td>
<td>3.4</td>
</tr>
</tbody>
</table>

Gastro-Intestinal function
By the modified release expression is co-conducted with medicine affecting GI tract physiology also discussion related to MR lozenge form must be done.

Quotidian Measures
Tube attention profile measured for 24 hrs at steady state of any difference occurs in view of Day/night.

Point of operation
The immersion of medicine at different point must be delved of the operation point in not limited to one body area.

Cure jilting
The chances of unanticipated release of medicine...
performing in inferior advanced exposure do when the MR expression contains advanced compared to immediate release product.

Tablets

Oral tablets are the most common, accessible, and easy system for medicine administration. Tablets are conventionally made by compressing medicine greasepaint with applicable excipi-ents that affect in rapid-fire release of the medicine in the body when taken. The debit of conventional tablets is that rapid-fire medicine release makes it delicate to maintain multi-component medicine release. Numerous controlled medicine release-grounded technologies similar as matrix tablets, multilayer tablets, Dome-matrix grounded tablets, core-in-mug bias, three-dimensional (3D) tablets, etc., have been developed or are under development (41-43) to deal with the downsides faced in conventional tablets. Matrix-tablets have been developed to attack the controlled medicine delivery issues faced in conventional tablets (Fig. 1) (44-48). The advantages of matrix tablets include lower frequent dosing, cost effectiveness, side-effect reduction from cure jilting, etc. Matrix-grounded systems are divided into three types 1) bulibous pump systems; 2) force matrix systems; and 3) megalith matrix systems. The bulibous pressure plays an important part in bulibous pump systems in which a semipermeable membrane with an perforation controls the medicine release. In the case of force matrix systems, a membrane controls the prolixity of the medicine from the system, whereas, in megalith matrix systems, the medicine has been dispersed or reprised in a hydrophobic or hydrophilic system, which controls the medicine release.

Multilayered tablets, including bilayered, triadic concentrated, and quadruple concentrated, etc., can be designed to release multiple medicines at different rates and are superior to conventional tablets. In general, the multilayered tablets correspond of a medicine core that's gridled by a hydrophobic or hydrophilic polymer subcaste that controls the medicine release in the GIT. Numerous multilayered tablets have been developed, similar as Geomatrix multilayer tablet technology, Smartrix technology, Sodas multilayer tablet technology, VersaTab bilayered tablet technology, Geolock technology, Procise technology, Chronotropic, Canons, etc. (Table 2) (49-53). The pate matrix-grounded medicine-releasing bias correspond of a pate-shaped swellable matrix module with a convex front and hollow base as shown in Fig. 2. These tablets have two configurations 1) void configuration and 2) piled configuration. The medicine release patterns in case of pate-matrix tablets are controlled by the configuration of modules (). A advanced medicine release rate has been observed for the convex front in comparison with the hollow base. The pate-matrix tablets showed a advanced original medicine release rate compared with conventional tablets. Dragged delivery of norfloxacin as pate-matrix tablet ways has also been established in the once 56, 57), but due to the complexity of these module systems, these tablets aren't as popular as other controlled release systems yet. To the stylish of our knowledge, this technology is still at exploratory position. Still, similar technologies will have significant impact in treating acute/habitual conditions involving multiple progres- sion pathways, where multiple medicines are demanded to block the complaint progress.

Polymer-grounded 3D published tablets have been fabricated to maintain controlled medicine release over a particular time period to retain the remedial position of the medicine input. The 3D published tablets can be produced by colorful styles similar as 3D inkjet printing (58, 59), an extrusion-grounded (60-64), or a fused deposit modeling (65-69). These tablets demonstrate high medicine lading and immediate medicine release while maintaining the active physical form of the medicine. The size, as well as the shape of the simulated tablets can be modified according to the substantiated use. These tablets can also be fabricated with a large number of shorter perforated channels with particular range and length to control the medicine release as the show in Fig. 3.

Roberts and associates (74) fabricated a 3D polypill with multiple active medicine motes con-fined in well-defined promised chambers for con- combed medicine release for the treatment of hypertension in type I diabetic cases. Captopril, glipizide, and nifedipine were used to make a 3D polypill (Fig. 4). The captopril medicine release was maintained through an zilches-motic pump-grounded medium, whereas glipizide and ni-fedipine showed the Korsmeyer-Peppas release kinetics. The study showed that a 3D polypill was suitable to deliver all three medicines without any sensible commerce between them.
Fig. 1. Image showing drug release from the matrix tablets. Adapted and modified from\textsuperscript{[70]}.

### TABLE 2
Summary of various advanced tablet technologies Adapted and Modified from\textsuperscript{[71-73]}.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Technology Design</th>
<th>Factors Affecting Drug Release</th>
<th>Advantages</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venlafaxine</td>
<td>Procise Drug core with a hole</td>
<td>Core geometry Zero-order kinetics or drug release(2015)</td>
<td>Malewar et al.</td>
<td></td>
</tr>
<tr>
<td>hydrochloride</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indomethacin</td>
<td>Smartrix Multilayer tablet with specific shape of core layer</td>
<td>Polymer type, Zero-order kinetics or drug release(2017) according to shape of core layer</td>
<td>Omer et al.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>Sodas (spheroidal oral drug absorption system) Multilayer tablet</td>
<td>Layer thickness, shape of core layer</td>
<td>Pulsatile drug release</td>
<td>Biederman et al.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norfloxacin</td>
<td>Dome matrix Dome-shaped swellable matrix module</td>
<td>Polymer module arrangement</td>
<td>Drug release based on module arrangement</td>
<td>Oliveira et al.  (2011)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenofibrate</td>
<td>3D printed tablets Fabrication through 3D</td>
<td>Polymer used, Immediate controlled</td>
<td>controlled release</td>
<td>Khaled et al. (2015);</td>
</tr>
<tr>
<td>captopril, glipizide, and nifedipine Insulin, camostat</td>
<td></td>
<td></td>
<td></td>
<td>Kyobula et al.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Permeation enhancement technology</th>
<th>Polymer layer, immediate or modified release</th>
<th>(Year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heparin</td>
<td>GIPET</td>
<td>controlled release</td>
<td>(2011)</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>Peptellig</td>
<td>Immediate or modified release</td>
<td>(2006)</td>
</tr>
<tr>
<td>Insulin, lactulose</td>
<td>CODES Multilayer tablet</td>
<td>Immediate pH-controlled release</td>
<td>(2012)</td>
</tr>
</tbody>
</table>

The aim of these technologies is to enhance the bioavailability of drug molecules. Many of the above mentioned technologies are under clinical trials, but there are still numerous challenges that need to be tackled to use these technologies in real time. A summary of various controlled release tablet technologies has been done below (Table 2).

---

**Fig. 2.** (A) Dome matrix tablet module with void configuration (B) and piled configuration (C). Adapted and modified from [76-78].

**Fig. 3.** Image showing perforated channels in 3D channeled tablet: (A) parallel and (B) at right angle to long axis. Adapted and modified from [76-78].
Multilayered Tablet:
The multilayered tablet approach is an accessible system in which the lading cure is squeezed between two external matrix layers. The central subcaste releases the cure for immediate onset of action whereas the matrix subcaste for sustained release of medicine. This helps in maintaining the blood position. The multilayered tablets are prepared by direct contraction or wet granulation or tablet contraction. The polymer used is ethyl cellulose, Eudragit RS 100. The challenges faced during multilayered tabletting include cross impurity from one subcaste to other (79-81).

Illustration if the first subcaste is red and alternate is white any granulation bypass the first confluent and pollute leading to pink color.

Uses:
Two inharmonious actives or excipients are compressed into one to make a high weight tablet. Control release and time release.

Imprinting (molecular):
Molecular imprinting provides lithography system and technology for operation in the manufacturing, areas similar as Nano-bias, advanced packaging, microstructure, memoir bias, semiconducting bias and optic factors (82-85).

The conception behind the technology is to fester a material around individual motes. When the molecular templates are removed, one is left template patch. This shows that molecular imprinting is applicable to that material that can widely bind to motes of interest.

Working of molecular imprinting:
Three introductory constituents are needed videlicet templates patch, functional monomers and a cross linker. The templates motes may range from small organic motes to large biopolymers. The templates must be purified, catalyzed or detected with the final product. These bear analogous to high energy interceders in the chemical response. Functional monomer should have two functional group each one end they should interact with templates with weak commerce (non-covalent) with the cross linkier. Cross linkers is a patch that can be polymerized around the templates, binding covalently to the functional monomers and holding them in place after the templates in removed pervious cross linkers or those which can be broken into small pieces are used generally (86-90).

Accudep technology:
Accudep technology has been developed for products for immediate release lozenge form, super general products ment, new controlled release phrasings. The main thing of this technology is to identify largely flexible delivery design that will accommodate numerous medicines of different physicochemical characteristics and cure grease engineering of immediate as well as control release of active pharmaceutical greasepaint. This process excludes processer similar as mixing blending, granulation, drying, contractionetc. and uses active component in pure form and achieves control release by the use of polymeric flicks (91-93).

In the process, the pharmaceutical maquillages acting as a color are charged, also transported to a chamber where in dissipation and disposition takes place.

Technology:
For medication of oral cure unit i.e. Accudep core is separated by erosional polymer flicks.
Illustrates It contains 6 layers each contains and each subcaste contains accudep core which in turn contained by a polymer core the layers are separated by rate controlling flicks and an impermeable coating is applied to the lozenge form.

The variables that affected medicine release include rate controlling film composition, quantum of medicine per subcaste, number of layers, immediate release rudiments, extend of content by on co passable coating. Rate controlling flicks was prepared with cellulosic material, polyethylene oxide film (94-100).

II. CONCLUSION

The oral route of administration is the most preferred route by patients for gastrointestinal drug delivery.

REFERENCES:


